Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | General Counsel | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 184,607 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Exercise / conversion · Acquired 34,090 · Balance 184,607 F1: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan. F2: Includes the unvested portion of the Reporting Person's RSU grants. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2027-08-30 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Exercise / conversion · Disposed 34,090 · Balance 0 F3: The option is fully vested and has been completely exercised. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
F2: Includes the unvested portion of the Reporting Person's RSU grants.
F3: The option is fully vested and has been completely exercised.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 16:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,090 | $2.57 Strike: $2.57 | $87,747.66 |
DisclosureSEC source: 0001836662-26-000005 · wk-form4_1781296090.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,090 shares Expires 2027-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and has been completely exercised. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 16:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 34,090 | $2.57 | $87,747.66 |
DisclosureSEC source: 0001836662-26-000005 · wk-form4_1781296090.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001836662-26-000002 · wk-form4_1769476892.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001836662-26-000002 · wk-form4_1769476892.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,734 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 17:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 6,810 | $22.16 | $150,906.20 |
DisclosureSEC source: 0001836662-25-000005 · wk-form4_1766097342.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,734 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 17:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 7,658 | $21.88 | $167,589.97 |
DisclosureSEC source: 0001836662-25-000005 · wk-form4_1766097342.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,544 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 1 share purchased on November 30, 2025 through the Company's Employee Stock Purchase Plan. F4 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 16:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000021 · wk-form4_1738013456.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 16:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000021 · wk-form4_1738013456.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,623 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 20:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 11,339 | $16.08 | $182,331.12 |
DisclosureSEC source: 0001724521-24-000183 · wk-form4_1734485805.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,623 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 16:53 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 4,182 | $16.97 | $70,968.54 |
DisclosureSEC source: 0001724521-24-000126 · wk-form4_1718744028.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,364 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes 967 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 19:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 108,200 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000027 · wk-form4_1706229568.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,200 Underlying: Common Stock · 108,200 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 19:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000027 · wk-form4_1706229568.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,579 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 16:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 4,076 | $18.09 | $73,734.84 |
DisclosureSEC source: 0001724521-23-000070 · wk-form4_1703106643.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,879 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 16:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 3,991 | $17.74 | $70,800.34 |
DisclosureSEC source: 0001724521-23-000070 · wk-form4_1703106643.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,955 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 44 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 20:17 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 2,892 | $19.35 | $55,960.20 |
DisclosureSEC source: 0001209191-23-038160 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,902 F1 · shares: Represents shares sold by the Issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.86 to $19.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 1,255 shares purchased on 5/31/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 17:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 138,200 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-004874 · doc4.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,200 Underlying: Common Stock · 138,200 shares Expires 2033-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 17:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004874 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,539 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 16, 2022 Filed Dec 16, 2022 21:42 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 398 | $31.23 | $12,429.54 |
DisclosureSEC source: 0001209191-22-061761 · doc4.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,584 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.05 to $31.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2022 Filed Dec 16, 2022 21:42 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,125 | $30.66 | $65,152.50 |
DisclosureSEC source: 0001209191-22-061761 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,982 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.05 to $31.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 16:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,073 | $22.29 | $23,917.17 |
DisclosureSEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 3 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,909 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 16:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 449 | $21.71 | $9,747.79 |
DisclosureSEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,982 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.14 to $22.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,400 | $20.72 | $29,008.00 |
DisclosureSEC source: 0001209191-22-038399 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 1,017 shares purchased on 5/31/2022 through the Company's Employee Stock Purchase Plan Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 17:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-22-017989 · doc4.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-03-07 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 17:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017989 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,814 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 225 | $41.42 | $9,320.36 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 6 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,564 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F8 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $41.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 171 | $40.57 | $6,938.02 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 5 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,789 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $41.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 88 | $39.67 | $3,491.13 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 4 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,960 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 138 | $38.79 | $5,352.70 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 3 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,048 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 131 | $40.46 | $5,299.80 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,186 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 356 | $39.59 | $14,094.61 |
DisclosureSEC source: 0001209191-21-070568 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,317 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 176 shares purchased on 11/30/2021 through the Company's Employee Stock Purchase Plan Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,606 | $23.68 | $38,030.08 |
DisclosureSEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 3 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,362 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 52 | $24.77 | $1,288.04 |
DisclosureSEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,968 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:54 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,257 | $24.13 | $30,331.41 |
DisclosureSEC source: 0001209191-21-042082 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,020 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 2,679 shares purchased on 5/28/2021 through the Company's Employee Stock Purchase Plan Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 16:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 75,225 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004280 · doc4.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,225 Underlying: Common Stock · 75,225 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 16:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 12,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004280 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,886 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.